You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Nintedanib

Showing 26 - 50 of 215
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Trends in Quality of Life in Idiopathic Pulmonary Fibrosis Under

Active, not recruiting
  • Idiopathic Pulmonary Fibrosis
  • Nintedanib
  • Alexandroupoli, Greece
  • +9 more
Aug 22, 2022

Lung Diseases, Interstitial Trial in China (nintedanib, Placebo)

Recruiting
  • Lung Diseases, Interstitial
  • nintedanib
  • Placebo
  • Beijing, China
  • +15 more
Jan 23, 2023

Dose Reduction and Discontinuation With Anti-Fibrotic

Not yet recruiting
  • Idiopathic Pulmonary Fibrosis
  • Ridgefield, Connecticut
    Boehringer Ingelheim
Mar 24, 2023

Myositis Associated Interstitial Lund Disease (MA-ILD) Trial in United States (Nintedanib, Placebo, Standard of Care)

Not yet recruiting
  • Myositis Associated Interstitial Lund Disease (MA-ILD)
  • Nintedanib
  • +2 more
  • Los Angeles, California
  • +14 more
Mar 22, 2023

Pulmonary Fibrosis, Interstitial Lung Disease, Respiratory Disease Trial in United States (Nintedanib, Placebo)

Recruiting
  • Pulmonary Fibrosis
  • +2 more
  • Nintedanib
  • Placebo
  • Phoenix, Arizona
  • +7 more
Oct 9, 2022

Lung Diseases, Interstitial Trial in Belgium (nintedanib)

Available
  • Lung Diseases, Interstitial
  • nintedanib
  • Aalst, Belgium
  • +13 more
Aug 8, 2022

Endometrial Cancer Trial in Copenhagen (Nintedanib or Placebo; Carboplatin, Paclitaxel)

Completed
  • Endometrial Cancer
  • Nintedanib or Placebo; Carboplatin, Paclitaxel
  • Copenhagen, Sjaelland, Denmark
    NSGO
Jan 7, 2022

Nintedanib in Indian Patients With Idiopathic Pulmonary Fibrosis

Completed
  • Idiopathic Pulmonary Fibrosis
    • Chennai, India
    • +9 more
    Aug 22, 2022

    Drug Drug Interaction Trial in Miami (Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral

    Completed
    • Drug Drug Interaction
    • Pirfenidone 267 mg Oral Tablet
    • +2 more
    • Miami, Florida
      Advanced Pharma
    Apr 14, 2022

    Adenocarcinoma of the Lung Trial in Großhansdorf (nintedanib-nivolumab combination therapy)

    Active, not recruiting
    • Adenocarcinoma of the Lung
    • nintedanib-nivolumab combination therapy
    • Großhansdorf, Germany
      LungenClinic Grosshansdorf
    Dec 14, 2021

    Nintedanib in Indian Non-small Cell Lung Cancer After First-line

    Completed
    • Non-small Cell Lung Cancer
      • Anand, India
      • +10 more
      Oct 12, 2022

      Telangiectasia, Hereditary Hemorrhagic, Rendu Osler Disease Trial in France (Nintedanib 150 mg and 100 mg soft capsules, Oral

      Recruiting
      • Telangiectasia, Hereditary Hemorrhagic
      • Rendu Osler Disease
      • Nintedanib 150 mg and 100 mg soft capsules
      • Oral treatment of placebo soft capsule
      • Angers, France
      • +9 more
      Mar 16, 2022

      Healthy Trial in Biberach (nintedanib (formulation A, test treatment), nintedanib (formulation B, reference treatment))

      Completed
      • Healthy
      • nintedanib (formulation A, test treatment)
      • nintedanib (formulation B, reference treatment)
      • Biberach, Germany
        Humanpharmakologisches Zentrum Biberach
      Sep 9, 2021

      Lung Cancer, Lung Metastases Trial in United States (Nintedanib, Prednisone, Placebo)

      Active, not recruiting
      • Lung Cancer
      • Lung Metastases
      • Nintedanib
      • +2 more
      • Boston, Massachusetts
      • +11 more
      Jul 19, 2022

      Idiopathic Pulmonary Fibrosis Trial in Seongnam-si (DWN12088, Pirfenidone, Nintedanib)

      Completed
      • Idiopathic Pulmonary Fibrosis
      • Seongnam-si, Korea, Republic of
        Cha Unitersity Bundang Medical Center
      Sep 22, 2021

      Progressive Fibrosing Interstitial Lung Disease Trial in Morgantown (Nintedanib, Placebo)

      Not yet recruiting
      • Progressive Fibrosing Interstitial Lung Disease
      • Nintedanib
      • Placebo
      • Morgantown, West Virginia
        West Virginia University Hospital
      Sep 29, 2021

      All-Case Surveillance of Ofev in Patients With IPF in Japan

      Recruiting
      • Idiopathic Pulmonary Fibrosis
      • Nintedanib
      • Multiple Locations, Japan
        (unnamed)
      Jan 23, 2023

      Based on Medical Records That Looks at Characteristics of

      Completed
      Has Results
      • Idiopathic Pulmonary Fibrosis
      • Nintedanib
      • +2 more
      • Plymouth, Pennsylvania
        Plymouth Meeting
      Nov 12, 2021

      Lung Diseases, Interstitial Trial in Worldwide (Nintedanib (Ofev®))

      Recruiting
      • Lung Diseases, Interstitial
      • Nintedanib (Ofev®)
      • Los Angeles, California
      • +29 more
      Jan 9, 2023

      Progressive Idiopathic Pulmonary Fibrosis Trial in France (pirfenidone and nintedanib, pirfenidone or nintedanib)

      Recruiting
      • Progressive Idiopathic Pulmonary Fibrosis
      • pirfenidone and nintedanib
      • pirfenidone or nintedanib
      • Angers, France
      • +15 more
      Jan 20, 2022

      INREAL - Nintedanib for Changes in Dyspnea and Cough in Patients

      Recruiting
      • Lung Diseases, Interstitial
      • Nintedanib
      • Aachen, Germany
      • +19 more
      Jul 26, 2022

      Idiopathic Pulmonary Fibrosis Trial in San Francisco, Boston, New York (EGCG 300 mg + Nintedanib, EGCG 300 mg + Pirfenidone,

      Not yet recruiting
      • Idiopathic Pulmonary Fibrosis
      • EGCG + Nintedanib
      • +2 more
      • San Francisco, California
        UCSF Parnassus
      Apr 25, 2022

      Ofev Capsules in Chronic Fibrosing Interstitial Lung Diseases

      Active, not recruiting
      • Lung Diseases, Interstitial
      • Nintedanib
      • Tokyo, Japan
        Nippon Boehringer Ingelheim Co., Ltd.
      Jan 9, 2023

      Cancer of Pancreas Trial in Dallas (Nintedanib)

      Recruiting
      • Cancer of Pancreas
      • Nintedanib
      • Dallas, Texas
        University of Texas Southwestern Medical Center
      Jul 29, 2021

      Idiopathic Pulmonary Fibrosis Trial in Canada (60% Oxygen, Standard of Care)

      Recruiting
      • Idiopathic Pulmonary Fibrosis
      • 60% Oxygen
      • Standard of Care
      • Calgary, Alberta, Canada
      • +7 more
      May 17, 2022